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Summary Carcinoma of the oesophagus is endemic in certain well demarcated areas throughout the world,
and a method of screening population groups at high risk for oesophageal cancer is urgently needed. In this
study the sensitivity and specificity of the carbohydrate antigen CA19-9 as a marker of carcinoma of the
oesophagus in African patients was examined. The normal range was established by assay of serum samples
from healthy black blood donors, using a solid phase radioimmunoassay with mouse monoclonal antibody to
CAl9-9 labelled with 125I. Serum concentrations of CA19-9 were then measured in 100 African patients with
oesophageal cancer and 28 patients with benign oesophageal disease. The upper limit of CA19-9 in the
normal controls was 40 Uml-1. Thirty-four patients with oesophageal cancer and five with benign
oesophageal disease had elevated levels. Therefore, in this series, the sensitivity of CA19-9 as a marker of
oesophageal cancer was 34% and the specificity was 82%. While CA19-9 is not sufficiently sensitive to be
used as a screening test of oesophageal cancer, it compares favourably with other known tumour markers of
this disease, and may have a role in monitoring disease recurrence and response to treatment.
Carcinoma of the oesophagus is the commonest cancer in
South Africa (McGlashen, 1988). However, patients do not
develop symptoms until an advanced stage of the disease. By
the time of diagnosis, 85% have no hope of cure. In South
Africa, those at greatest risk for the development of this
malignancy have been clearly identified: they are black men,
aged 40-60 years who frequently smoke and drink
(Kneebone & Mannell, 1985). A simple method of screening
this group is urgently needed: only by detecting oesophageal
cancer in its early asymptomatic stage can these patients be
cured of the disease.
Circulating tumour associated antigens, products of neo-
plastic cells which are secreted in excessive quantities into the
blood stream, offer great potential in the early detection of
cancer. When a specific marker of oesophageal carcinoma is
identified, a simple blood test could be used to screen
patients at risk for the development of this malignancy.
Carbohydrate antigen (CA19-9) is the specific carbo-
hydrate fraction of a circulating antigen found in the serum
of normal adults (Koprowski et al., 1981). Excessive quanti-
ties of this antigen have been found in patients with
gastrointestinal malignancies, including colorectal, pancreatic
and hepatocellular carcinomas (Ritts et al., 1984; Kew et al.,
1987). The oesophagus, like the pancreas and liver, is a
foregut derivative and it is possible that oesophageal car-
cinoma may also express this antigen.
The aim of this study was to measure serum concen-
trations of CA19-9 in black patients with oesophageal cancer
and in those with benign oesophageal disease. The normal
range was established by assays of serum samples from
apparently healthy, age and sex-matched black subjects. The
sensitivity and specificity of CA19-9 as a marker of
squamous carcinoma of the oesophagus was then examined.
Materials and methods
Patient groups
Cancer of the oesophagus One hundred consecutive African
patients with carcinoma of the oesophagus, admitted to
Baragwanath Hospital, Johannesburg from September 1987
to October 1988, were included, having given informed
consent for this study. There were 80 men and 20 women
aged 21-84 years (mean age 59). In each case the diagnosis
of oesophageal cancer was established by a barium swallow
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examination and oesophageal biopsy; 99 patients had squa-
mous carcinoma and one patient adenocarcinoma of the
oesophagus. No patient had received specific anticancer
therapy before this study.
Benign oesophageal disease This group consisted of 28
African patients with oesophagitis, diagnosed by endoscopic
examination and confirmed by biopsy who had all given
informed consent for the CA19-9 assay. There were 12 men
and 16 women aged 25-71 years (mean age 52).
Controls To determine the normal range in healthy Afri-
cans, serum was obtained from 21 black blood donors aged
21-66 years (mean age 43) who were free of the hepatitis B
surface antigen.
Methods
Blood samples, obtained by peripheral venipuncture, were
centrifuged and the separated serum stored at -20°C, within
2h of collection. The serum samples were assayed for
CA19-9 using a solid phase radioimmunoassay (Centocor
CA19-9 Tm RIA system, Centocor Inc.) based on the
'forward sandwich' principle and utilising mouse monoclonal
antibody to CA19-9 labelled with 125I.
Analysis of data
CA19-9 levels greater than the upper limit in the normal
controls were considered elevated and levels below the upper
limit of normal as non-elevated. CA19-9 levels were reported
to the nearest one-tenth Uml-1. The Welch one-way analy-
sis of variance was the test employed to identify differences
between the patient groups and the controls. After logarith-
mic transformation of the data, the pairwise t test was used
to re-examine these differences. Sensitivity was defined as the
number of patients with cancer of the oesophagus with an
elevated assay level divided by the total number of patients
with cancer of the oesophagus. Specificity was defined as the
number of patients with benign oesophageal disease with
non-elevated levels divided by the total number of patients
with benign oesophageal disease. The positive predictive
value of the test is the ratio of the number of cancer patients
with an elevated assay level to the total number of patients
with elevated levels. The negative predictive value of the test
is the ratio of the number of non-cancer patients with a non-
elevated assay level to the total number of patients with non-
elevated levels.
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Results
The distribution of CA19-9 levels for the healthy controls,
patients with oesophageal cancer and patients with benign
oesophageal disease is summarised in Table I.
The upper limit of CA19-9 in the normal controls was
40Uml-1. Thirty-four patients with oesophageal cancer and
five patients with benign oesophageal disease had elevated
levels. The sensitivity of CA19-9 as a test for oesophageal
cancer was therefore 34% and the specificity was 82%. The
positive predictive value of the test was 87% and the
negative predictive value was 26%.
Statistical analysis
The CA19-9 levels in the two patient groups were signifi-
cantly different from those of the normal controls (Welch
test, P=0.001). However, after pairwise comparison of the
mean CA19-9 levels, before and after logarithmic trans-
formation of the data, no significant difference was identified
between patients with oesophageal cancer and those with
benign oesophageal disease.
Discussion
Monoclonal antibodies are beginning to acquire important
practical implications in current medicine practice and
monoclonal antibodies to cancer antigens offer great poten-
tial in the early detection of malignant disease activity as
well as response to therapy (Torosian, 1988; Vugrin et al.,
1984). The populations at risk for the development of
squamous carcinoma of the oesophagus have been clearly
identified in such countries as South Africa, China, Iran and
France (Kneebone & Mannell, 1985; Isaacson et al., 1978;
Yang, 1980; Mufioz et al., 1982; Faivre et al., 1981). But
there is very little published data on the use of monoclonal
antibodies to detect tumour associated antigens in the serum
of patients with oesophageal cancer in these endemic areas.
Early studies of the oncofetal antigens, including carcino-
embryonic antigen (CEA) and alpha-fetoprotein (AFP) have
proved disappointing. Serum CEA levels greater than
lOngml-l were detected in 10% (Wahren et al., 1979) and
31% (Alexander et al., 1978) of patients with untreated
oesophageal cancer in earlier studies. A later series of 162
cases with proven squamous oesophageal cancer showed that
only 5% of patients had an elevated CEA level at the time
of diagnosis (Melissas et al., 1983).
AFP has proved even more disappointing. Using a cut-off
point of 15ngml- 1, Wahren et al. (1979) noted elevated
AFP levels in 3.6% of patients with squamous carcinoma.
No patient with oesophageal cancer in the small number
reported by McIntire et al. (1975) at the Mayo Clinic had
elevated AFP levels. However, recent work using monoclonal
antibodies to detect squamous cell carcinoma antigen
(SCCA) in patients with oesophageal cancer is more encour-
aging. Elias (1988) reported that this serological marker, first
described in patients with squamous carcinoma of the cervix
(Kato & Torigoe, 1977), was elevated in 23.5% of patients
with carcinoma of the oesophagus.
Although the CA19-9 assay was originally developed to
detect patients with colorectal adenocarcinoma (Koprowski
et al., 1981), subsequent work revealed that the serum levels
of this antigen were raised in a greater proportion of patients
with pancreatic and hepatobiliary malignancies than those
with large bowel cancer (Ritts et al., 1984; Kew et al., 1987).
The oesophagus, like the pancreas and the liver, is a foregut
derivative and this study was undertaken in the hope that
CA19-9 might prove a useful tumour marker for oesopha-
geal carcinoma.
The evaluation of a tumour marker necessitates investi-
gation of benign conditions which could be considered in the
differential diagnosis of the tumour for the presence of the
marker. Benign tumours of the oesophagus are rare
(Gowing, 1961). Therefore, patients with oesophagitis, the
most common benign condition of the oesophagus which can
also present with dysphagia, were investigated for the
presence of CA19-9 in the serum. Ritts et al. (1984), in a
series of eight patients with oesophageal cancer, noted one
patient (13%) to have a CA19-9 level of >40Uml-1. Our
series has shown that elevated levels of CA19-9 are present
in 34% of patients with oesophageal cancer at the time of
diagnosis. These results compare very favourably with simi-
lar studies of other tumour markers in carcinoma of the
oesophagus. But it is evident that CA19-9 is not sufficiently
sensitive or specific for use as a screening test of population
at risk for this malignancy. The reason why five of the 28
patients with oesophagitis also had elevated levels of CA19-9
is uncertain. One possible explanation lies in the fact that
monoclonal antibodies to CA19-9 react with a high molecu-
lar weight mucin antigen as well as a low molecular weight
ganglioside (Steinberg et al., 1986) and that inflammation of
the oesophagus may lead to an increased production of
mucin by the oesophageal mucus-secreting glands. Antigens
derived from the oesophageal mucus if present in the
circulation, could then be recognised by the anti CA19-9
monoclonal antibodies.
Another explanation possible is that oesophagitis in black
patients could be a pre-malignant condition (E. Dowdle,
personal communication, 1988). Support for this hypothesis
would require mass screening of the African population at
risk by both CA19-9 assay and endoscopic examination of
the oesophagus, a study which is not feasible at this time.
Although CA19-9 does not fulfil the requirements of an
ideal serological tumour marker (Torosian, 1988) for oeso-
phageal cancer, it may have value in monitoring disease
recurrence or response to therapy, similar to the role of CEA
in the follow-up of patients treated for colorectal tumours
(Mayer et al., 1978; Mach et al., 1974). For this reason serial
assays of CA19-9 are currently being performed in those
patients in this study who have been treated for oesophageal
cancer, and will be the subject of a later report.
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Table I CA19-9 levels in different groups
CA19-9 levels (Uml-1)
1st 3rd
Group Number Mean (s.d.) quantile Median quantile Range
Normal 21 14.9 (9.7) 7.0 12 20 7-40
Oesophageal cancer 100 38.3(45.9) 7.3 26 50 3-240
Benign oesophageal disease 28 26.3(19.0) 7.3 21 40 7-80CA19-9 AND OESOPHAGEAL CANCER 251
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